Trinity Biotech Plc

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trinity Biotech reports robust Q1 results, eyes $75M revenue milestone

Trinity Biotech's Q1 2024 performance reflects strong revenue growth, margin improvement, and cost optimization efforts. Despite challenges in compliance and operational optimization, the company is poised for growth with a clear focus on key priorities and revenue targets.

Trinity Biotech reports revenue growth and operational progress in Q2

Trinity Biotech's Q2 2024 performance showed revenue growth and operational improvements, with a focus on strategic transformation and market expansion.
While facing financial challenges and cost pressures, the company is leveraging strengths in point-of-care sales and technology advancement for future success.
Opportunities for growth and profitability exist through achieving revenue targets, optimizing operations, and driving innovation in key product lines.
Overall, Trinity Biotech's progress in Q2 2024 sets a foundation for future growth and value creation, underpinned by a clear strategic roadmap.

Trinity Biotech reports growth in Q3, eyes new technology revenue

Trinity Biotech's Q3 performance showed revenue growth and progress towards financial targets. Strategic strengths in growth focus and cost optimization position the company for future success. Challenges include lower revenues and restructuring costs, while opportunities lie in new technology revenue streams and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results

DUBLIN, Ireland, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on September 8, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 555(a)(2), as the minimum bid price of the Company's American depositary shares (“ADSs”) has been below US $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nasdaq Capital Market under the symbol “TRIB.”

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

DUBLIN, Ireland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification of hemoglobins F and A2, and the detection of >200 hemoglobin variants. The Premier Resolution System is now cleared for sale in the United States.

Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 2023.

Trinity Biotech Announces Q1 2023 Financial Results

DUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023. The Company has scheduled a conference call for that same day, July 6, 2023 at 11:00am ET (16:00pm BST) to discuss the results of the quarter.

Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results

DUBLIN, Ireland, April 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that it has closed the recently announced sale of its Fitzgerald Industries life sciences supply business, consisting of Benen Trading Ltd and Fitzgerald Industries International, Inc, to Biosynth for cash proceeds of approximately $30 million subject to customary adjustments. Biosynth is owned, amongst others, by KKR, Ampersand Capital Partners and management.

Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth

DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced it has entered into an agreement to sell its Fitzgerald Industries life sciences supply business, consisting of Benen Trading Ltd and Fitzgerald Industries International, Inc, to Biosynth for cash proceeds of approximately $30 million subject to customary adjustments. Biosynth is owned, amongst others, by KKR, Ampersand Capital Partners and management. The sale is expected to close in April 2023.

Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth

Trinity Biotech plc (NASDAQ:TRIB ) Q4 2022 Earnings Conference Call March 23, 2023 10:00 AM ET Company Participants Joe Diaz - Lytham Partners, Investor Relations Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Operator Good morning and welcome to the Trinity Biotech Fourth Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.

Trinity Biotech plc (TRIB) Q4 2022 Earnings Call Transcript

DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2022 and fiscal year 2022.

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results

DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today welcomed the announcement by the Kenyan Ministry of Health of the adoption of a new HIV rapid testing algorithm. This new algorithm establishes Trinity Biotech's TrinScreen HIV as the screening test (A1 = screen test under World Health Organisation (“WHO”) guidelines).

Trinity Biotech Welcomes TrinScreen HIV's Inclusion In The New Kenyan HIV Testing Algorithm

Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN

Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results

DUBLIN, Ireland, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced its entry into an increased loan facility to fund potential acquisitions and ongoing operations.

Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions

DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced a strategic partnership with imaware Inc that combines their built-to-partner digital health platform with Trinity Biotech's advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs.

Trinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry

Trinity Biotech plc (NASDAQ:TRIB ) Q3 2022 Earnings Conference Call December 15, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Fund Operator Good day. And welcome to the Trinity Biotech Third Quarter Financial Results Conference Call.

Trinity Biotech plc (TRIB) Q3 2022 Earnings Call Transcript

DUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended September 30, 2022.

Trinity Biotech Announces Q3 2022 Financial Results

Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN

Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results

DUBLIN, Ireland, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Aris Kekedjian, Chairman and Chief Executive Officer, and John Gillard, Chief Financial Officer, will represent the company in a session scheduled at 10:30am ET and will also host a number of 1-on-1 meetings with investors.

Trinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference

Trinity Biotech plc (NASDAQ:TRIB ) Q2 2022 Results Conference Call November 3, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Operator Good day, and welcome to the Trinity Biotech Second Quarter Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Trinity Biotech plc (TRIB) Q2 2022 Earnings Call Transcript

DUBLIN, Ireland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended June 30, 2022 and preliminary guidance with respect to Q3 revenues.

Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance

Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results

DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces the appointment of Mr. Tom Lindsay to its Board of Directors as an independent non-executive director.

Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors

DUBLIN, Ireland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the appointment of Mr. Aris Kekedjian as CEO with effect from October 3, 2022. He succeeds Mr. Ronan O'Caoimh, co-founder of Trinity Biotech, who will remain on the Trinity Biotech plc Board of Directors to advise the Company going forward. In addition, Mr. Kekedjian has also assumed the role of Chairman of the Board of Directors of Trinity Biotech plc.

Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO

DUBLIN, Ireland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Annual General Meeting (AGM).

Trinity Biotech Announces Results of AGM

Trinity Biotech plc (NASDAQ:TRIB ) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan O'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode.

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2022 Results - Earnings Call Transcript

DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 2022.

News for Trinity Biotech Plc Stock (TRIB)